Ginkgo Bioworks (DNA) Financials

$6.78 -0.21 (-3.00%)

Closing price 05/27/2025 03:59 PM Eastern

Extended Trading

$6.95 +0.17 (+2.45%)

As of 04:25 AM Eastern

Annual Income Statements for Ginkgo Bioworks

This table shows Ginkgo Bioworks' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Income / (Loss) Attributable to Common Shareholders	-547	-893	-2,105
Consolidated Net Income / (Loss)	-547	-893	-2,106
Net Income / (Loss) Continuing Operations	-547	-893	-2,106
Total Pre-Tax Income	-548	-893	-2,121
Total Operating Income	-560	-864	-2,209
Total Gross Profit	182	197	273
Total Revenue	227	251	478
Operating Revenue	227	251	478
Total Cost of Revenue	45	54	204
Operating Cost of Revenue	45	54	204
Total Operating Expenses	742	1,062	2,482
Selling, General & Admin Expense	246	385	1,430
Research & Development Expense	424	581	1,053
Impairment Charge	48	96	0.00
Restructuring Charge	24	0.00	0.00
Total Other Income / (Expense), net	12	-29	88
Interest Expense	0.09	0.09	0.11
Interest & Investment Income	2.77	-43	-45
Other Income / (Expense), net	9.57	14	133
Income Tax Expense	-0.48	-0.07	-15
Net Income / (Loss) Attributable to Noncontrolling Interest	0.00	0.00	-1.44
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)	-1.49	0.00	0.00
Basic Earnings per Share	($10.54)	($18.37)	($50.15)
Weighted Average Basic Shares Outstanding	51.89M	48.61M	41.98M
Diluted Earnings per Share	($10.54)	($18.37)	($50.20)
Weighted Average Diluted Shares Outstanding	51.89M	48.61M	42.00M
Weighted Average Basic & Diluted Shares Outstanding	58.03M	2.15B	1.95B

This table shows Ginkgo Bioworks' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	-109	-55	-217	-166	-212	-303	-173	-205	-175	-670
Consolidated Net Income / (Loss)	-108	-56	-217	-166	-212	-303	-173	-205	-173	-670
Net Income / (Loss) Continuing Operations	-108	-56	-217	-166	-212	-303	-173	-205	-173	-670
Total Pre-Tax Income	-108	-57	-217	-166	-212	-303	-173	-205	-188	-670
Total Operating Income	-104	-55	-223	-178	-178	-286	-184	-216	-231	-655
Total Gross Profit	34	77	42	29	28	49	62	58	68	42
Total Revenue	44	89	56	38	35	55	81	81	98	66
Operating Revenue	44	89	56	38	35	55	81	81	98	66
Total Cost of Revenue	9.62	12	14	9.20	6.61	6.92	18	22	30	25
Operating Cost of Revenue	9.62	12	14	9.20	6.61	6.92	18	22	30	25
Total Operating Expenses	138	132	265	207	206	335	247	274	299	697
Selling, General & Admin Expense	57	52	66	70	89	82	102	111	121	435
Research & Development Expense	76	77	134	136	117	157	144	163	178	261
Total Other Income / (Expense), net	-4.25	-1.57	5.95	12	-34	-17	11	11	43	-15
Interest & Investment Income	17	-4.67	-6.83	-2.54	3.58	-36	-2.19	-7.82	17	-8.48
Other Income / (Expense), net	1.05	3.10	2.47	2.96	6.65	4.78	-1.26	4.13	35	-13
Income Tax Expense	-0.33	-0.38	0.19	0.03	-0.20	-0.02	0.07	0.08	-15	-0.03
Basic Earnings per Share	($2.10)	($1.08)	($0.11)	($0.08)	($4.35)	($6.21)	($0.09)	($0.11)	($4.18)	($0.41)
Weighted Average Basic Shares Outstanding	51.89M	52.24M	2.05B	2.00B	48.61M	48.77M	1.93B	1.91B	41.98M	1.63B
Diluted Earnings per Share	($2.10)	($1.08)	($0.11)	($0.08)	($4.35)	($6.21)	($0.09)	($0.11)	($4.18)	($0.41)
Weighted Average Diluted Shares Outstanding	51.89M	52.25M	2.06B	2.01B	48.61M	48.77M	1.93B	1.92B	42.00M	1.63B
Basic & Diluted Earnings per Share	($2.10)	-	-	-	($4.35)	-	-	-	($4.18)	-
Weighted Average Basic & Diluted Shares Outstanding	58.03M	57.48M	2.22B	2.21B	2.15B	2.12B	1.98B	2.09B	1.95B	1.94B

This table details how cash moves in and out of Ginkgo Bioworks' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Change in Cash & Equivalents	-384	-380	-223
Net Cash From Operating Activities	-320	-296	-252
Net Cash From Continuing Operating Activities	-320	-296	-252
Net Income / (Loss) Continuing Operations	-547	-893	-2,106
Consolidated Net Income / (Loss)	-547	-893	-2,106
Depreciation Expense	63	71	43
Non-Cash Adjustments To Reconcile Net Income	275	498	1,878
Changes in Operating Assets and Liabilities, net	-111	29	-66
Net Cash From Investing Activities	-62	-81	-67
Net Cash From Continuing Investing Activities	-62	-81	-67
Purchase of Property, Plant & Equipment	-63	-41	-52
Acquisitions	-5.40	0.00	75
Purchase of Investments	0.00	-43	-59
Sale of Property, Plant & Equipment	0.65	4.43	0.00
Sale and/or Maturity of Investments	4.52	0.00	10
Other Investing Activities, net	0.54	-1.34	-40
Net Cash From Financing Activities	-1.74	-3.22	95
Net Cash From Continuing Financing Activities	-1.74	-3.22	95
Repurchase of Common Equity	-0.00	-0.58	-1.47
Issuance of Common Equity	0.00	0.00	99
Other Financing Activities, net	-1.74	-2.64	-2.50
Effect of Exchange Rate Changes	-0.28	-0.59	0.91

This table details how cash moves in and out of Ginkgo Bioworks' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	-56	-114	-111	-102	-105	-77	-87	-111	24	-75
Net Cash From Operating Activities	-42	-104	-84	-89	-58	-74	-74	-91	-105	-28
Net Cash From Continuing Operating Activities	-42	-104	-84	-89	-58	-74	-74	-91	-105	-28
Net Income / (Loss) Continuing Operations	-108	-56	-217	-166	-212	-303	-173	-205	-173	-670
Consolidated Net Income / (Loss)	-108	-56	-217	-166	-212	-303	-173	-205	-173	-670
Depreciation Expense	16	17	17	13	13	21	18	19	16	8.92
Non-Cash Adjustments To Reconcile Net Income	53	37	121	64	101	214	92	91	90	593
Changes in Operating Assets and Liabilities, net	-3.48	-101	-5.28	-0.61	40	-5.24	-10	4.00	-37	41
Net Cash From Investing Activities	-13	-10	-27	-12	-47	-3.38	-11	-19	30	-46
Net Cash From Continuing Investing Activities	-13	-10	-27	-12	-47	-3.38	-11	-19	30	-59
Purchase of Property, Plant & Equipment	-14	-15	-27	-6.71	-3.45	-4.38	-14	-19	-26	-13
Sale of Property, Plant & Equipment	0.06	0.40	-	-	1.43	0.07	-	-	-0.11	0.11
Sale and/or Maturity of Investments	0.57	-	-	-	-	-	-	-	-	-
Net Cash From Financing Activities	-0.20	-0.47	-0.23	-0.85	-0.63	-0.32	-1.38	-0.89	98	-0.39
Net Cash From Continuing Financing Activities	-0.20	-0.47	-0.23	-0.85	-0.63	-0.32	-1.38	-0.89	98	-0.39
Other Financing Activities, net	-0.20	-0.46	-0.23	-0.85	-0.66	-0.31	-1.36	-0.31	-1.07	-0.30
Effect of Exchange Rate Changes	-0.07	-0.04	-0.02	-0.16	0.10	-0.20	-0.47	-0.03	1.10	-0.09

This table presents Ginkgo Bioworks' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Total Assets	1,377	1,665	2,539
Total Current Assets	603	1,002	1,450
Cash & Equivalents	562	944	1,316
Accounts Receivable	22	18	82
Prepaid Expenses	19	40	52
Plant, Property, & Equipment, net	204	188	315
Total Noncurrent Assets	571	475	774
Long-Term Investments	49	79	114
Goodwill	0.00	49	60
Intangible Assets	73	83	111
Other Noncurrent Operating Assets	450	265	489
Total Liabilities & Shareholders' Equity	1,377	1,665	2,539
Total Liabilities	661	568	803
Total Current Liabilities	107	164	173
Accounts Payable	14	9.32	10
Accrued Expenses	65	110	115
Current Deferred Revenue	28	44	48
Total Noncurrent Liabilities	554	404	630
Noncurrent Deferred Revenue	99	158	175
Other Noncurrent Operating Liabilities	455	246	455
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	716	1,097	1,736
Total Preferred & Common Equity	716	1,097	1,736
Preferred Stock	0.00	0.00	0.00
Total Common Equity	716	1,097	1,736
Common Stock	6,555	6,386	6,137
Retained Earnings	-5,838	-5,291	-4,398
Accumulated Other Comprehensive Income / (Loss)	-1.81	1.48	-2.63

This table presents Ginkgo Bioworks' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	1,481	1,625	1,582	2,026	2,292	2,417	1,871
Total Current Assets	662	783	903	1,142	1,223	1,327	1,462
Cash & Equivalents	616	730	840	1,049	1,106	1,206	1,303
Accounts Receivable	24	19	25	63	69	85	116
Prepaid Expenses	22	34	38	29	48	34	38
Plant, Property, & Equipment, net	211	211	196	202	294	314	188
Total Noncurrent Assets	607	631	483	683	774	776	221
Long-Term Investments	62	62	76	86	1.12	1.19	4.14
Goodwill	0.00	0.00	48	58	59	59	29
Intangible Assets	80	91	77	100	105	109	48
Other Noncurrent Operating Assets	466	478	281	439	609	607	140
Total Liabilities & Shareholders' Equity	1,481	1,625	1,582	2,026	2,292	2,417	1,871
Total Liabilities	683	792	594	774	788	810	431
Total Current Liabilities	114	166	169	168	163	192	125
Accounts Payable	16	23	27	11	14	22	11
Accrued Expenses	76	117	108	115	110	123	73
Current Deferred Revenue	23	26	34	43	39	48	41
Total Noncurrent Liabilities	569	626	425	605	625	618	306
Noncurrent Deferred Revenue	105	153	166	170	180	175	172
Other Noncurrent Operating Liabilities	463	473	259	435	445	443	75
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	798	833	987	1,253	1,504	1,608	1,440
Total Preferred & Common Equity	798	833	987	1,253	0.00	0.00	1,435
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	798	833	987	1,253	1,504	1,608	1,435
Common Stock	6,528	6,508	6,445	6,334	6,281	6,212	5,669
Retained Earnings	-5,730	-5,674	-5,456	-5,079	-4,776	-4,603	-4,226
Accumulated Other Comprehensive Income / (Loss)	0.26	-1.72	-1.55	-2.90	-1.30	-1.61	-7.91

This table displays calculated financial ratios and metrics derived from Ginkgo Bioworks' official financial filings.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Growth Metrics	-	-	-
Revenue Growth	-9.71%	-47.36%	52.21%
EBITDA Growth	37.51%	61.67%	-18.33%
EBIT Growth	35.28%	59.06%	-18.80%
NOPAT Growth	35.24%	60.87%	-20.81%
Net Income Growth	38.73%	57.61%	-14.69%
EPS Growth	42.62%	57.61%	-14.69%
Operating Cash Flow Growth	-8.15%	-17.17%	0.64%
Free Cash Flow Firm Growth	-13.48%	80.93%	-77.67%
Invested Capital Growth	41.96%	-75.71%	399.41%
Revenue Q/Q Growth	4.17%	-20.17%	-9.51%
EBITDA Q/Q Growth	12.83%	2.69%	40.74%
EBIT Q/Q Growth	11.13%	2.79%	40.11%
NOPAT Q/Q Growth	11.75%	5.75%	39.69%
Net Income Q/Q Growth	16.00%	-4.52%	40.47%
EPS Q/Q Growth	15.27%	-4.52%	40.47%
Operating Cash Flow Q/Q Growth	4.60%	13.65%	19.48%
Free Cash Flow Firm Q/Q Growth	5.19%	34.19%	0.00%
Invested Capital Q/Q Growth	-11.57%	-36.50%	59.07%
Profitability Metrics	-	-	-
Gross Margin	80.38%	78.52%	57.25%
EBITDA Margin	-214.57%	-310.03%	-425.74%
Operating Margin	-246.54%	-343.76%	-462.41%
EBIT Margin	-242.33%	-338.07%	-434.65%
Profit (Net Income) Margin	-240.94%	-355.08%	-440.93%
Tax Burden Percent	99.91%	99.99%	99.29%
Interest Burden Percent	99.51%	105.04%	102.17%
Effective Tax Rate	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-434.65%	-317.41%	-1,513.72%
ROIC Less NNEP Spread (ROIC-NNEP)	-415.64%	-293.93%	-1,477.58%
Return on Net Nonoperating Assets (RNNOA)	374.31%	254.38%	1,386.20%
Return on Equity (ROE)	-60.34%	-63.02%	-127.52%
Cash Return on Invested Capital (CROIC)	-469.34%	-195.58%	-637.47%
Operating Return on Assets (OROA)	-36.16%	-40.44%	-90.07%
Return on Assets (ROA)	-35.96%	-42.47%	-91.38%
Return on Common Equity (ROCE)	-60.34%	-63.02%	-125.12%
Return on Equity Simple (ROE_SIMPLE)	-76.39%	-81.38%	-121.32%
Net Operating Profit after Tax (NOPAT)	-392	-605	-1,546
NOPAT Margin	-172.58%	-240.63%	-323.69%
Net Nonoperating Expense Percent (NNEP)	-19.01%	-23.47%	-36.14%
Return On Investment Capital (ROIC_SIMPLE)	-54.72%	-55.15%	-89.06%
Cost of Revenue to Revenue	19.62%	21.48%	42.75%
SG&A Expenses to Revenue	108.42%	153.12%	299.31%
R&D to Revenue	186.78%	230.90%	220.35%
Operating Expenses to Revenue	326.92%	422.28%	519.66%
Earnings before Interest and Taxes (EBIT)	-550	-850	-2,076
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-487	-780	-2,034
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	0.79	3.26	1.89
Price to Tangible Book Value (P/TBV)	0.88	3.71	2.09
Price to Revenue (P/Rev)	2.49	14.24	6.86
Price to Earnings (P/E)	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	34.32	6.03
Enterprise Value to Revenue (EV/Rev)	0.00	10.17	3.87
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00
Financial Leverage	-0.90	-0.87	-0.94
Leverage Ratio	1.68	1.48	1.40
Compound Leverage Factor	1.67	1.56	1.43
Debt to Total Capital	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00
Altman Z-Score	-6.14	-1.60	-1.88
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	1.88%
Liquidity Ratios	-	-	-
Current Ratio	5.62	6.11	8.38
Quick Ratio	5.44	5.87	8.08
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-423	-373	-1,955
Operating Cash Flow to CapEx	-516.35%	-812.42%	-482.48%
Free Cash Flow to Firm to Interest Expense	-4,501.04	-4,009.08	-18,447.87
Operating Cash Flow to Interest Expense	-3,399.84	-3,177.42	-2,379.23
Operating Cash Flow Less CapEx to Interest Expense	-4,058.28	-3,568.53	-2,872.35
Efficiency Ratios	-	-	-
Asset Turnover	0.15	0.12	0.21
Accounts Receivable Turnover	11.26	5.01	4.46
Inventory Turnover	0.00	0.00	0.00
Fixed Asset Turnover	1.16	1.00	2.07
Accounts Payable Turnover	3.79	5.46	21.91
Days Sales Outstanding (DSO)	32.43	72.84	81.76
Days Inventory Outstanding (DIO)	0.00	0.00	0.00
Days Payable Outstanding (DPO)	96.24	66.82	16.66
Cash Conversion Cycle (CCC)	-63.81	6.02	65.10
Capital & Investment Metrics	-	-	-
Invested Capital	106	75	307
Invested Capital Turnover	2.52	1.32	4.68
Increase / (Decrease) in Invested Capital	31	-232	409
Enterprise Value (EV)	-46	2,558	1,849
Market Capitalization	564	3,580	3,279
Book Value per Share	$12.46	$0.52	$0.90
Tangible Book Value per Share	$11.20	$0.46	$0.81
Total Capital	716	1,097	1,736
Total Debt	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00
Net Debt	-610	-1,023	-1,430
Capital Expenditures (CapEx)	62	36	52
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-66	-106	-39
Debt-free Net Working Capital (DFNWC)	495	838	1,277
Net Working Capital (NWC)	495	838	1,277
Net Nonoperating Expense (NNE)	155	288	560
Net Nonoperating Obligations (NNO)	-610	-1,023	-1,430
Total Depreciation and Amortization (D&A)	63	71	43
Debt-free, Cash-free Net Working Capital to Revenue	-29.11%	-42.23%	-8.10%
Debt-free Net Working Capital to Revenue	218.23%	333.22%	267.34%
Net Working Capital to Revenue	218.23%	333.22%	267.34%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($10.54)	($18.40)	($50.00)
Adjusted Weighted Average Basic Shares Outstanding	51.89M	48.61M	41.98M
Adjusted Diluted Earnings per Share	($10.54)	($18.40)	($50.00)
Adjusted Weighted Average Diluted Shares Outstanding	51.89M	48.61M	42.00M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	58.03M	53.81M	48.81M
Normalized Net Operating Profit after Tax (NOPAT)	-341	-538	-1,546
Normalized NOPAT Margin	-150.37%	-213.85%	-323.69%
Pre Tax Income Margin	-241.15%	-355.11%	-444.08%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	-5,853.04	-9,140.86	-19,588.19
NOPAT to Interest Expense	-4,168.40	-6,506.28	-14,587.42
EBIT Less CapEx to Interest Expense	-6,511.48	-9,531.97	-20,081.31
NOPAT Less CapEx to Interest Expense	-4,826.84	-6,897.39	-15,080.54
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	-0.07%	-0.07%

This table displays calculated financial ratios and metrics derived from Ginkgo Bioworks' official financial filings.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	26.16%	60.65%	-30.24%	-52.98%	-64.64%	-16.52%	-44.29%	-52.08%	-33.81%	-14.45%
EBITDA Growth	45.22%	86.59%	-21.10%	15.82%	11.95%	60.47%	72.72%	66.75%	88.59%	-1,477.42%
EBIT Growth	40.19%	81.50%	-18.91%	17.28%	12.44%	57.85%	70.29%	64.04%	87.66%	-1,234.38%
NOPAT Growth	41.83%	80.72%	-21.07%	17.49%	22.85%	56.27%	71.57%	68.06%	86.30%	-2,355.53%
Net Income Growth	49.20%	81.38%	-25.31%	19.06%	-22.31%	54.80%	74.15%	65.41%	89.22%	-554.39%
EPS Growth	51.72%	82.61%	-22.22%	27.27%	-22.31%	54.80%	78.05%	70.27%	89.22%	-412.50%
Operating Cash Flow Growth	26.62%	-40.72%	-14.76%	1.46%	44.68%	-159.34%	26.03%	-355.25%	36.85%	-441.76%
Free Cash Flow Firm Growth	-196.50%	67.26%	168.86%	149.84%	118.84%	83.82%	-137.17%	-142.69%	0.00%	-853.60%
Invested Capital Growth	41.96%	1.94%	-89.86%	-82.31%	-75.71%	-39.15%	69.13%	185.57%	399.41%	259.14%
Revenue Q/Q Growth	-50.76%	58.43%	48.13%	9.18%	-37.30%	-31.20%	-0.17%	-17.89%	48.02%	-54.09%
EBITDA Q/Q Growth	-148.76%	82.80%	-25.26%	-2.24%	39.12%	-55.31%	12.92%	-6.93%	72.67%	-7.18%
EBIT Q/Q Growth	-96.83%	76.37%	-25.95%	-2.09%	39.11%	-51.89%	12.38%	-8.06%	70.69%	-7.05%
NOPAT Q/Q Growth	-87.68%	75.24%	-25.25%	0.06%	37.81%	-55.52%	14.64%	6.55%	64.75%	-1.11%
Net Income Q/Q Growth	-90.65%	74.03%	-30.90%	21.63%	30.11%	-74.76%	15.44%	-18.43%	74.17%	0.07%
EPS Q/Q Growth	-94.44%	-881.82%	-37.50%	27.27%	30.11%	-74.76%	18.18%	-10.00%	74.17%	0.00%
Operating Cash Flow Q/Q Growth	59.00%	-22.65%	5.45%	-54.34%	21.37%	-0.02%	18.82%	13.34%	-268.57%	71.47%
Free Cash Flow Firm Q/Q Growth	-153.65%	-120.42%	-2.20%	90.50%	186.06%	57.06%	29.21%	27.97%	26.11%	-198.65%
Invested Capital Q/Q Growth	-11.57%	197.47%	-43.21%	-4.97%	-36.50%	-70.42%	-0.91%	30.50%	59.07%	-17.78%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	78.06%	86.52%	75.59%	75.75%	80.98%	87.51%	77.54%	72.27%	69.25%	62.87%
EBITDA Margin	-198.20%	-39.23%	-361.43%	-427.41%	-456.43%	-470.05%	-208.22%	-238.72%	-183.31%	-992.71%
Operating Margin	-236.29%	-61.99%	-396.66%	-469.12%	-512.49%	-516.68%	-228.57%	-267.34%	-234.89%	-986.38%
EBIT Margin	-233.90%	-58.51%	-392.27%	-461.33%	-493.37%	-508.04%	-230.13%	-262.22%	-199.25%	-1,006.14%
Profit (Net Income) Margin	-245.25%	-63.34%	-386.40%	-437.25%	-609.10%	-546.44%	-215.12%	-253.98%	-176.10%	-1,009.26%
Tax Burden Percent	99.70%	99.34%	100.09%	100.02%	99.91%	99.99%	100.04%	100.04%	92.14%	100.00%
Interest Burden Percent	105.17%	108.97%	98.42%	94.76%	123.57%	107.57%	93.44%	96.82%	95.92%	100.31%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-416.58%	-79.83%	-234.30%	-290.93%	-473.20%	-734.53%	-165.24%	-270.06%	-768.93%	-10,172.41%
ROIC Less NNEP Spread (ROIC-NNEP)	-412.29%	-77.87%	-227.87%	-287.04%	-466.10%	-725.93%	-161.60%	-266.04%	-768.19%	-10,158.24%
Return on Net Nonoperating Assets (RNNOA)	371.29%	68.87%	185.26%	234.93%	403.39%	642.30%	128.38%	221.40%	720.69%	9,920.15%
Return on Equity (ROE)	-45.28%	-10.96%	-49.04%	-56.01%	-69.82%	-92.23%	-36.86%	-48.66%	-48.25%	-252.26%
Cash Return on Invested Capital (CROIC)	-469.34%	-376.63%	-114.15%	-105.77%	-195.58%	-365.27%	-336.54%	-549.37%	-637.47%	0.00%
Operating Return on Assets (OROA)	-34.91%	-7.27%	-36.92%	-48.15%	-59.01%	-82.13%	-35.00%	-45.71%	-41.29%	-264.17%
Return on Assets (ROA)	-36.60%	-7.87%	-36.37%	-45.64%	-72.85%	-88.33%	-32.72%	-44.27%	-36.49%	-264.99%
Return on Common Equity (ROCE)	-45.28%	-10.96%	-49.04%	-56.01%	-69.82%	-92.05%	-36.48%	-48.15%	-47.34%	-246.36%
Return on Equity Simple (ROE_SIMPLE)	0.00%	-81.61%	-107.76%	-86.48%	0.00%	-68.19%	0.00%	0.00%	0.00%	-246.62%
Net Operating Profit after Tax (NOPAT)	-73	-39	-156	-125	-125	-200	-129	-151	-162	-458
NOPAT Margin	-165.40%	-43.40%	-277.66%	-328.38%	-358.75%	-361.67%	-160.00%	-187.13%	-164.42%	-690.47%
Net Nonoperating Expense Percent (NNEP)	-4.29%	-1.96%	-6.43%	-3.89%	-7.10%	-8.60%	-3.64%	-4.02%	-0.74%	-14.18%
Return On Investment Capital (ROIC_SIMPLE)	-10.13%	-	-	-	-11.36%	-	-	-	-9.31%	-
Cost of Revenue to Revenue	21.94%	13.48%	24.41%	24.25%	19.02%	12.49%	22.46%	27.73%	30.75%	37.13%
SG&A Expenses to Revenue	130.67%	58.72%	117.93%	185.24%	256.72%	147.98%	127.02%	138.08%	123.50%	655.47%
R&D to Revenue	174.19%	86.48%	238.80%	359.63%	336.75%	282.63%	179.08%	201.53%	180.65%	393.78%
Operating Expenses to Revenue	314.35%	148.52%	472.25%	544.87%	593.47%	604.19%	306.11%	339.61%	304.15%	1,049.25%
Earnings before Interest and Taxes (EBIT)	-103	-52	-220	-175	-171	-282	-185	-212	-196	-668
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-87	-35	-203	-162	-159	-261	-168	-193	-180	-659
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.79	0.57	0.89	2.53	3.26	2.86	2.58	1.62	1.89	3.88
Price to Tangible Book Value (P/TBV)	0.88	0.63	1.00	2.90	3.71	3.27	2.90	1.80	2.09	4.10
Price to Revenue (P/Rev)	2.49	2.08	4.01	11.96	14.24	11.37	11.90	6.66	6.86	10.55
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	22.32	34.32	20.85	6.99	3.47	6.03	22.44
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	7.57	10.17	7.77	8.50	3.56	3.87	8.20
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.04
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.04
Financial Leverage	-0.90	-0.88	-0.81	-0.82	-0.87	-0.88	-0.79	-0.83	-0.94	-0.98
Leverage Ratio	1.68	1.71	1.68	1.54	1.48	1.45	1.40	1.39	1.40	1.32
Compound Leverage Factor	1.76	1.86	1.65	1.46	1.83	1.56	1.30	1.34	1.34	1.32
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	3.99%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	3.99%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.33%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	95.67%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-0.02
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.36
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-0.02
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-0.02
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.49
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-0.02
Altman Z-Score	-5.07	-4.54	-4.21	-1.99	-0.25	-0.46	0.47	-0.31	0.56	4.55
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.19%	1.03%	1.04%	1.88%	2.34%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	5.62	5.79	4.71	5.34	6.11	6.78	7.49	6.92	8.38	11.71
Quick Ratio	5.44	5.59	4.51	5.12	5.87	6.60	7.19	6.73	8.08	11.36
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-104	-41	200	205	108	-125	-291	-411	-571	-772
Operating Cash Flow to CapEx	-310.81%	-704.62%	-312.19%	-1,330.24%	-2,865.76%	-1,707.71%	-543.36%	-465.95%	-405.87%	-212.24%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	2.44	0.00	0.00	0.00	-66.58	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	-1.31	0.00	0.00	0.00	-12.19	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	-1.36	0.00	0.00	0.00	-15.20	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.15	0.12	0.09	0.10	0.12	0.16	0.15	0.17	0.21	0.26
Accounts Receivable Turnover	11.26	5.01	4.20	3.82	5.01	3.52	2.67	3.05	4.46	6.34
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	26.18	22.45	25.19	0.00	51.55
Fixed Asset Turnover	1.16	1.06	0.73	0.82	1.00	1.62	1.39	1.68	2.07	3.20
Accounts Payable Turnover	3.79	3.14	1.99	1.68	5.46	7.03	5.76	4.97	21.91	26.11
Days Sales Outstanding (DSO)	32.43	72.92	86.93	95.67	72.84	103.65	136.50	119.75	81.76	57.55
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	13.94	16.26	14.49	0.00	7.08
Days Payable Outstanding (DPO)	96.24	116.23	183.51	217.07	66.82	51.91	63.34	73.47	16.66	13.98
Cash Conversion Cycle (CCC)	-63.81	-43.31	-96.58	-121.40	6.02	65.69	89.42	60.77	65.10	50.66
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	106	120	40	71	75	117	397	400	307	193
Invested Capital Turnover	2.52	1.84	0.84	0.89	1.32	2.03	1.03	1.44	4.68	14.73
Increase / (Decrease) in Invested Capital	31	2.28	-356	-330	-232	-75	162	260	409	314
Enterprise Value (EV)	-46	-225	-54	1,580	2,558	2,446	2,772	1,390	1,849	4,327
Market Capitalization	564	453	739	2,497	3,580	3,582	3,879	2,597	3,279	5,569
Book Value per Share	$12.46	$0.36	$0.38	$0.46	$0.52	$0.63	$0.72	$0.82	$0.90	$0.88
Tangible Book Value per Share	$11.20	$0.32	$0.34	$0.40	$0.46	$0.55	$0.64	$0.74	$0.81	$0.83
Total Capital	716	798	833	987	1,097	1,253	1,504	1,608	1,736	1,500
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	60
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	60
Net Debt	-610	-678	-793	-916	-1,023	-1,135	-1,107	-1,207	-1,430	-1,247
Capital Expenditures (CapEx)	14	15	27	6.71	2.02	4.31	14	19	26	13
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-66	-68	-113	-106	-106	-76	-46	-70	-39	35
Debt-free Net Working Capital (DFNWC)	495	548	617	734	838	973	1,060	1,136	1,277	1,337
Net Working Capital (NWC)	495	548	617	734	838	973	1,060	1,136	1,277	1,337
Net Nonoperating Expense (NNE)	35	18	61	41	87	102	44	54	11	212
Net Nonoperating Obligations (NNO)	-610	-678	-793	-916	-1,023	-1,135	-1,107	-1,207	-1,430	-1,247
Total Depreciation and Amortization (D&A)	16	17	17	13	13	21	18	19	16	8.92
Debt-free, Cash-free Net Working Capital to Revenue	-29.11%	-31.27%	-61.39%	-51.01%	-42.23%	-24.08%	-14.01%	-18.07%	-8.10%	6.55%
Debt-free Net Working Capital to Revenue	218.23%	251.46%	334.83%	351.70%	333.22%	309.03%	325.24%	291.18%	267.34%	253.30%
Net Working Capital to Revenue	218.23%	251.46%	334.83%	351.70%	333.22%	309.03%	325.24%	291.18%	267.34%	253.30%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($2.10)	($1.08)	($4.40)	($3.20)	($174.00)	($6.40)	($3.60)	($4.40)	($167.20)	($16.40)
Adjusted Weighted Average Basic Shares Outstanding	51.89M	52.24M	51.37M	50.11M	1.22M	48.77M	48.34M	47.87M	1.05M	40.77M
Adjusted Diluted Earnings per Share	($2.10)	($1.08)	($4.40)	($3.20)	($174.00)	($6.40)	($3.60)	($4.40)	($167.20)	($16.40)
Adjusted Weighted Average Diluted Shares Outstanding	51.89M	52.25M	51.38M	50.13M	1.22M	48.77M	48.34M	47.92M	1.05M	40.77M
Adjusted Basic & Diluted Earnings per Share	($2.10)	$0.00	$0.00	$0.00	($174.00)	$0.00	$0.00	$0.00	($167.20)	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	58.03M	57.48M	55.58M	55.28M	53.81M	52.96M	49.47M	52.14M	48.81M	48.50M
Normalized Net Operating Profit after Tax (NOPAT)	-73	-37	-111	-125	-125	-133	-129	-151	-162	-458
Normalized NOPAT Margin	-165.40%	-41.08%	-196.80%	-328.38%	-358.75%	-240.17%	-160.00%	-187.13%	-164.42%	-690.47%
Pre Tax Income Margin	-245.99%	-63.76%	-386.06%	-437.17%	-609.67%	-546.48%	-215.03%	-253.88%	-191.13%	-1,009.31%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	-3.90	0.00	0.00	0.00	-22.84	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	-2.83	0.00	0.00	0.00	-18.85	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	-3.94	0.00	0.00	0.00	-25.85	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	-2.88	0.00	0.00	0.00	-21.85	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	-0.07%	0.00%	0.00%	-0.12%	-0.07%	0.00%

Frequently Asked Questions About Ginkgo Bioworks' Financials

When does Ginkgo Bioworks's financial year end?

According to the most recent income statement we have on file, Ginkgo Bioworks' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Ginkgo Bioworks' net income changed over the last 2 years?

Ginkgo Bioworks' net income appears to be on a downward trend, with a most recent value of -$547.03 million in 2024, falling from -$2.11 billion in 2022. The previous period was -$892.87 million in 2023. See where experts think Ginkgo Bioworks is headed by visiting Ginkgo Bioworks' forecast page.

What is Ginkgo Bioworks's operating income?

Ginkgo Bioworks's total operating income in 2024 was -$559.76 million, based on the following breakdown:

Total Gross Profit: $182.50 million
Total Operating Expenses: $742.25 million

How has Ginkgo Bioworks revenue changed over the last 2 years?

Over the last 2 years, Ginkgo Bioworks' total revenue changed from $477.71 million in 2022 to $227.04 million in 2024, a change of -52.5%.

How much debt does Ginkgo Bioworks have?

Ginkgo Bioworks' total liabilities were at $661.39 million at the end of 2024, a 16.4% increase from 2023, and a 17.6% decrease since 2022.

How much cash does Ginkgo Bioworks have?

In the past 2 years, Ginkgo Bioworks' cash and equivalents has ranged from $561.57 million in 2024 to $1.32 billion in 2022, and is currently $561.57 million as of their latest financial filing in 2024.

How has Ginkgo Bioworks' book value per share changed over the last 2 years?

Over the last 2 years, Ginkgo Bioworks' book value per share changed from 0.90 in 2022 to 12.46 in 2024, a change of 1,291.9%.

Related Companies

This page (NYSE:DNA) was last updated on 5/28/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ginkgo Bioworks (DNA) Financials

Frequently Asked Questions About Ginkgo Bioworks' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ginkgo Bioworks (DNA) Financials

Annual Income Statements for Ginkgo Bioworks

Quarterly Income Statements for Ginkgo Bioworks

Annual Cash Flow Statements for Ginkgo Bioworks

Quarterly Cash Flow Statements for Ginkgo Bioworks

Annual Balance Sheets for Ginkgo Bioworks

Quarterly Balance Sheets for Ginkgo Bioworks

Annual Metrics And Ratios for Ginkgo Bioworks

Quarterly Metrics And Ratios for Ginkgo Bioworks

Frequently Asked Questions About Ginkgo Bioworks' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools